Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729901 | 1.00 | GLS (0.57) | GLSIDO1MEN1KMT2AEPHX2 | |
| SCHEMBL5435879 | 0.86 | GLS (0.61) | GLSKMT2ACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1728790 | 0.86 | GLS (0.64) | GLSMAPTCNR1ACHECNR2 | |
| SCHEMBL11002083 | 0.83 | GLS (0.67) | GLSMEN1KMT2AMAPTADORA2A | |
| SCHEMBL3506368 | 0.83 | GLS (0.54) | GLSADORA2AADORA1RECQL | |
| SCHEMBL3376313 | 0.83 | GLS (0.54) | GLSMEN1KMT2AEPHX2PPARG | |
| SCHEMBL29377015 | 0.82 | GLS (0.58) | GLSEGFRERBB2GRIN1GRIN2B | |
| SCHEMBL27083759 | 0.82 | GLS (0.58) | GLSEGFRERBB2GRIN1GRIN2B | |
| SCHEMBL16213110 | 0.81 | ERBB2 (0.61) | MEN1KMT2AEGFRERBB2CYP1A2 | |
| SCHEMBL3378095 | 0.81 | GLS (0.57) | GLSGRIN1GRIN2BMAPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-104744446-B | Heteroaryl compound and its application in drug | 广东东阳光药业有限公司 | 2019-06-25 | — | — | CN | disclosed |
| US-9168253-B2 | Quinazoline compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-10-27 | — | — | US | disclosed |
| US-9168253-B2 | Quinazoline compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-10-27 | — | — | US | disclosed |
| CN-104744446-A | Hetero-aromatic compound and application thereof in medicine | GUANGDONG HEC PHARMACEUTICAL | 2015-07-01 | — | — | CN | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| CN-103304572-A | 3-cyanoquinoline compound as well as pharmaceutical composition and application thereof | SHANGHAI PHARMACEUTICAL GROUP CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | MASTALERZ HAROLD | 2005-09-22 | — | — | US | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-6908916-B2 | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| CN-1615306-A | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2005-05-11 | — | — | CN | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1446401-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | Bristol-Myers Squibb Company (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | disclosed |
| WO-2003042172-A2 | C-5 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186983-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | GLS 1787/4885IDO1 320/4885MEN1 2138/4885 |
| US-20050209235-A1 | C-5 Modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | GLS 1581/4885IDO1 364/4885MEN1 2738/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | GLS 148/4885IDO1 4012/4885MEN1 2095/4885 |
| US-20240059698-A1 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | EGFR, ERBB2, ERBB3 | GLS 477/4885IDO1 3487/4885MEN1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.